Q2 FY2026 · ended Jun 30, 2026 · Revenue $19.29M, -4.5% YoY · Filed Aug 11, 2026
TELA Bio, Inc. (TELA) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $19.3 million and a net loss of $11.3 million. Free cash flow was -$9.4 million. As of Jun 30, 2026 it held $30.4 million in cash and investments and $56.6 million in total debt.
Revenue
$19.29M
-4.5% vs year-ago quarter
Net income
$-11.26M
-13.5% vs year-ago quarter
Operating cash flow
$-9.38M
-18.7% vs year-ago quarter
Free cash flow
$-9.44M
-17.7% vs year-ago quarter
EPS
$-0.20
+9.1% vs year-ago quarter
Dividend per share
None
Shares outstanding
44.89M
+13.3% vs year-ago quarter
Net cash
$-26.19M
Q2 FY2026
Operating margin
-42.6%
TTM
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- TELA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Malvern, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1561921
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $19.3M | $19.1M | $20.9M | $20.7M | $20.2M |
| Operating income | -$9.3M | -$10.5M | -$6.6M | -$7.6M | -$9.1M |
| Net income | -$11.3M | -$12.3M | -$9.0M | -$8.6M | -$9.9M |
| Diluted EPS | -$0.20 | -$0.21 | -$0.17 | -$0.19 | -$0.22 |
| Operating cash flow | -$9.4M | -$11.2M | -$4.9M | -$5.7M | -$7.9M |
| Free cash flow | -$9.4M | -$11.3M | -$5.0M | -$5.9M | -$8.0M |
| Total assets | $59.7M | $69.9M | $81.4M | $61.6M | $67.5M |
| Total liabilities | $75.6M | $75.1M | $75.1M | $60.0M | $58.4M |
| Stockholders' equity | -$15.9M | -$5.2M | $6.3M | $1.6M | $9.2M |
| Cash and investments | $30.4M | $39.5M | $50.8M | $29.7M | $35.0M |
| Total debt | $56.6M | $56.4M | $57.7M | $42.0M | $41.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Shareholder vote results
|
Oct 8, 2026 | Oct 8, 2026 |
| 8-K |
Current report
Other events
|
Oct 6, 2026 | Oct 5, 2026 |
| 8-K |
Current report
Other events
|
Oct 5, 2026 | Oct 5, 2026 |
| 8-K |
Current report
Material agreement
|
Sep 29, 2026 | Sep 28, 2026 |
| 8-K |
Current report
Listing notice
|
Sep 18, 2026 | Sep 15, 2026 |
| 8-K |
Current report
Exit or restructuring costs, Officer or director change, Regulation FD disclosure
|
Aug 31, 2026 | Aug 28, 2026 |
All 545 TELA Bio, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.